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ROLE OF HIV-1 VPR IN REGULATION OF EXPRESSION OF 
UNINTEGRATED VIRAL DNA  
 
ZHANHAO XI 
 
ABSTRACT 
Vpr, one of the four accessory proteins in HIV-1, is expressed in all primate 
lentiviruses, and has been shown to facilitate viral replication through degradation of 
various host factors in a DCAFCrl4 E3 ubiquitin ligase dependent manner and induce a 
G2/M cell cycle arrest. But the underlying mechanism of Vpr-dependent replication 
enhancement has remained unclear. Previous studies from our laboratory and in the 
literature have demonstrated the ability of HIV-1 Vpr to mediate enhanced gene 
expression from the viral long terminal repeat (LTR) in a DCAFCrl4-dependent manner.  
In recently published studies, Vpx, a homolog of Vpr, expressed by HIV-2/SIVmac/SIVsm 
lineage of lentiviruses has been shown to enhance proviral gene expression through 
degradation of components in Human Silencing Hub (HUSH) complex by hijacking the 
DCAF1 mediated ubiquitin proteasome pathway. The aim of this study is to determine if 
HIV-1 Vpr has the same role as Vpx in promoting viral expression through degradation 
of HUSH complex components. I specifically focused on the role of Vpr in mediating 
enhanced viral gene expression from unintegrated viral DNA. Unintegrated viral DNA 
can be present as 1-LTR or 2-LTR circles when viral cDNA integration is blocked by use 
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of integrase inhibitors, such as Raltegravir, a commonly used drug in HIV treatment 
regimens. To assess Vpr’s role, I created HeLa cell lines in which expression of HUSH 
components, including the upstream SETDB1 protein, was diminished by use of targeted 
shRNAs. After assessing the knockdown efficiency using RT-qPCR, the cell lines are 
infected with luciferase expressing Vpr null (ΔVpr) or Wildtype (WT) HIV-1 that are 
normal or defective for viral DNA integration capability. Measurement of luciferase 
activity in infected cell lysates provided a quantitative measure of expression from viral 
DNA. Expression from unintegrated viral DNA was attenuated in the absence of Vpr 
compared to WT HIV-1. Furthermore, knockdown of HUSH complex subunits 
expression did not rescue luciferase reporter gene expression from unintegrated viral 
DNA in Vpr-null virus infections, suggesting that Vpr-mediated enhancement of viral 
gene expression from unintegrated viral DNA is not dependent on targeting HUSH 
complex functions. Future studies will be needed to fully understand the mechanism by 
which Vpr facilitates viral gene expression from unintegrated viral DNA.   
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INTRODUCTION 
Background to HIV 
In 2015, it was estimated that in the US more than 50% of HIV-1 individuals are 
50 years and older. WHO estimates that globally, there is 36.9 million people living with 
HIV-1 worldwide in 2017(“Global Health Observatory (GHO) Data” ), and 3.6 million 
are people who are over 50 years old. In 2017, data from CDC states that there are 38,738 
new HIV-1 diagnoses in the U.S. 
HIV-1 is transmitted through mucosal surfaces, maternal-infant exposure and 
percutaneous blood exposure(Shaw and Hunter 2012). After entering the blood, HIV-1 
targets CD4+ T cells for depletion, and render’s the patient’s immune system 
defective(Okoye and Picker 2013, 4). The host’s condition is then called acquired 
immune deficiency syndrome or AIDS(Simon, Ho, and Abdool Karim 2006), which was 
first described as a new disease in 1981(HIV.gov 2016). The condition was first widely 
seen in young homosexual men that are easily infected by opportunistic infections, which 
normal healthy adults would be immune to(Greene 2007). In addition, a rare form of 
cancer called Kaposi’s sarcoma, are often developed by these affected homosexual men, 
evident by dark purple lesions on their arms and faces(Greene 2007). The reason that 
homosexual men have a higher chance of acquiring HIV is due to the little protection that 
rectal compartment has, which is composed of a single layer columnar epithelium, 
compared to the multi-layered squamous and columnar epithelium in the 
vagina(Burgener, McGowan, and Klatt 2015). 
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Currently, there are two types of HIV that causes AIDS: HIV-1 and HIV-
2(Campbell-Yesufu and Gandhi 2011). There are many similarities between the two 
viruses, but also many differences; more than 90% of HIV+ patients worldwide are 
infected with HIV-1(Campbell-Yesufu and Gandhi 2011). HIV-1 also develops AIDS 
faster than HIV-2, and HIV-2 is spread less commonly, with most patients centralized in 
West Africa. Furthermore, the two viruses, HIV-1 and HIV-2, only share little sequence 
identity(Miyazaki et al. 2017). Thus, the origin of the viruses are speculated to be 
different. The origin of HIV-1 has been dated to around 1920s(Korber 2000), and is 
believed to be derived from another primate lentivirus, Simian immunodeficiency virus 
(SIVcpz), that infects chimpanzees. However, HIV-2 is believed to originate from SIV 
that infected sooty mangabey monkeys (Sharp and Hahn 2011).  
 
HIV-1  life cycle 
HIV-1 is a lentivirus, a subgroup of retrovirus, that reverse transcribes its RNA 
material into DNA, and inserts it into the host chromosome(R. Craigie and Bushman 
2012). It is difficult to cure because once the virus establishes infection by integrating its 
viral genome into the chromosome of the host’s CD4+ T cell, it will perpetually be there 
until the cell itself dies(R. Craigie and Bushman 2012). Although most of the infected 
cells die due to viral replication, few infected cells remain persistently infected, or 
become latently infected, where full length viral DNA is present, but not transcriptionally 
active due to nucleosome conformation, and awaits stimulation to activate transcription 
of viral LTR (Archin et al. 2009). Through cell division, these infected cells replicate 
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quiescently, evading immune surveillance throughout the process. Currently, there is no 
method to eradicate this viral reservoir once it is established, and patients have to be on 
lifelong treatment of antiretroviral therapy (ART) in order to suppress remission(Bhatti, 
Usman, and Kandi 2016).  
 
Figure 1: HIV Virion Structure(Steckbeck, Kuhlmann, and Montelaro 2013). 
Detailed depicture of viral components of a HIV virion. 2 positive-sense single-
stranded RNA protected by Nucleocapsid, Capsid, and Envelope. 
The steps of HIV infection after entering the host is for the HIV-1 envelope 
glycoprotein, gp120, to bind to CD4 receptor that is expressed on CD4+ T cells, 
macrophages and dendritic cells. The binding of gp120 to CD4 causes a conformational 
change in Env that allows it to further bind to one of the co-receptors, CCR5(R5 tropic) 
or CXCR4(X4 tropic)(Alkhatib et al. 1996). This exposes gp41, which pulls and fuses the 
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membranes together, allowing the delivery of viral material(Doms and Moore 2000). 
Inhibitors for fusion step of the viral life cycle include Maraviroc that antagonizes CCR5 
receptor(Kanmogne and Woollard 2015).  
After entering the cell, reverse transcription begins and reverse transcriptase uses 
host deoxyribonucleotides (dNTPs) to convert viral RNA into double stranded viral 
cDNA(Hu and Hughes 2012). Inhibitors of reverse transcriptase include Efavirenz, a 
Non-nucleoside Reverse Transcriptase Inhibitor, and Tenofovir, a Nucleoside Reverse 
Transcriptase Inhibitor(Gallant and Deresinski 2019). Pre-integration complex (PIC) then 
forms with integrase attached, and actively transported into the nucleus(Popov et al. 
1998).  
Integrase, is encoded by pol gene, and is responsible for processing viral cDNA, 
and integrating it into the host chromosome(Lee and Robinson 2004). The first step is 
cleaving 2 nucleotides from each 3’ end of the cDNA. The cleaved hydroxyl groups then 
attacks the phosphodiester bonds of chromosomal DNA. The intermediate integration 
step is then completed by cell repair mechanisms to cleave the 5’ end of viral cDNA, and 
ligate the 5’ ends to host chromosome(Robert Craigie 2012). The integration is then 
complete, and the viral cDNA will be part of the host cell chromosome. Depending on 
the state of CD4+ immune cell, histone modifications at the integration site might silence 
the viral cDNA transcription, or immediately available for transcription(Turner and 
Margolis, n.d.). 
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Figure 2: Tat binding location to TAR RNA with P-TEFb to increase 
transcriptional efficiency(Zhou and Yik 2006). Tat recognizes site at TAR RNA, 
then recruits P-TEFb to phosphorylate CTD. 
Transcription of viral cDNA uses host RNA polymerase II, which also requires P-
TEFb, and other co-factors that are recruited at the long terminal repeat (LTR)(Liu et al. 
2014). Tat protein, encoded by HIV-1 is important in controlling the elongation of viral 
transcription by greatly enhancing Pol II efficiency through binding to transactivation 
response RNA element (TAR)(Braddock et al. 1993). After P-TEFb is recruited by Tat 
that is bound to TAR, P-TEFb phosphorylates the C-terminal domain of RPB1 at the 
serine 2 position of Pol II(Barboric et al. 2000). The phosphorylation events inhibits the 
promoter-proximal pausing, allowing Pol II to transcribe full-length viral transcripts(Liu 
et al. 2014).    
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Figure 3: HIV-1 genome expression of alternatively spliced products(Mahiet 
and Swanson 2016). Gag and pol are contained in the unspliced mRNA, vif ,vpu, 
vpr, and env are contained in the singly spliced mRNA, containing one functional 
intro. Rev, tat and nef are expressed from fully spliced mRNA, and does not 
require special treat from its protein expression.  
With the integrated HIV-1 provirus being only 9.8 kb long, HIV-1 relies on alternative 
splicing to transcribe its nine genes(Watts et al. 2009). Unlike the fully spliced mRNA, 
unspliced mRNA requires Rev to actively shuttle the unprocessed mRNA out to the 
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cytoplasm(Fernandes, Jayaraman, and Frankel 2012). Rev binds to the Rev Response 
Element (RRE) on mRNA, and nuclear export protein CRM1, to shuttle the unprocessed 
mRNA out of the nucleus(Sertznig et al. 2018).  
Env polyprotein is transported through the Golgi apparatus to the cell membrane. 
During the transportation process, gp160 is cleaved by furin into gp41 and gp120 
(Hallenberger et al. 1992). After transcription, HIV-1 Gag-pol precursor protein 
assembles the virion at the membrane. At the amino terminus of Gag, Matrix (MA) binds 
to plasma membrane and recruits Env protein(Alfadhli et al. 2016). The membrane 
binding of MA is dependent on myristylation, and Capsid(CA) forms the capsid core that 
protects viral genomic material(Sundquist and Krausslich 2012). Nucleocapsid(NC) 
recognizes viral RNA, and helps it assemble at the Gag complex through recognition of 
psi packaging signal located at 5’ untranslated region of genomic RNA(D’Souza and 
Summers 2005). P6 domain is important for budding and release of immature virion, 
which is mediated by host Endosomal Sorting Complexes Required for Transport 
(ESCRT) machinery(Freed 2015). The virion requires a maturation process, which 
protease cleaves Gag-Pro-Pol polyprotein into Matrix, Capsid, Nucleocapsid, p6, 
protease, reverse transcriptase, and integrase proteins, and the proteins form the final 
structure of a mature virion(Könnyű et al. 2013).  
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Today, there exists many classes of drugs, some of which are used in the clinic to 
suppress HIV-1 replication in infected individuals. These drug classes include:  
Drug Class Drug Name Mechanism 
Nucleoside Reverse 
Transcriptase Inhibitors 
(NRTIs) 
Abacavir A carbocyclic 2’-deoxyguanosine 
analogue that has carbovir 
triphosphate phosphorylated. 
When it is incorporated into viral 
cDNA, reverse transcription 
terminates(Hervey and Perry 
2000). 
Emtricitabine A cytidine analog with 
5’triphosphate that terminates 
DNA elongation of reverse 
transcriptase once it is 
incorporated into cDNA(Mandal 
et al. 2017).  
Tenofovir An acyclic analog of d-AMP. 
Once incorporated into viral 
cDNA, elongation terminates due 
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to lack of hydroxyl group in the 3’ 
end(Ustianowski and Arends 
2015).  
Zidovudine A Thymidine analogue, with 3’ –
OH group replaced by azido 
group, that inhibits viral cDNA 
elongation when incorporated into 
viral cDNA by reverse 
transcriptase(Anderson and 
Rower 2010).  
Lamivudine It is an analogue of cytidine, and 
has the ability to inhibit both 
HIV-1 and HIV-2 reverse 
transcriptase by terminating 
reverse transcription. It is a 
negative enantiomer of dideoxy 3’ 
Thiacytidine(Quercia et al. 2018).  
Non-Nucleoside Reverse 
Transcriptase Inhibitors 
(NNRTIs)  
Doravirine A newer NNRTI that binds to 
allosteric site 10 Å away from 
reverse transcriptase active site, 
causing a conformational change, 
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and inhibiting the polymerization 
step.(Colombier and Molina 
2018) 
Efavirenz First generation NNRTI. Binds to 
p66 subunit of reverse 
transcriptase, thus inhibiting RT 
dimerization(Braz, Holladay, and 
Barkley 2010). 
Etravirine Second generation NNRTIs, have 
similar binding mode to 
Rilpivirine(Lansdon et al. 2010). 
Nevirapine Binds to reverse transcriptase 
residues Tyr-181 and Tyr-
188(CohenSg et al., n.d.). 
Rilpivirine Binds to allosteric site 10 Å away 
from reverse transcriptase’s active 
site.  
Fusion Inhibitors Enfuvirtide Drug competitively binds to HR1, 
and thus inhibiting fusion of gp41 
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with cell membrane(Hardy and 
Skolnik 2004). 
CCR5 Antagonists Maraviroc A nonpeptidic small molecule that 
inhibits the binding of HIV gp120 
to CCR5. Thus inhibiting viral 
fusion with cell 
membrane(Garcia-Perez et al. 
2011). 
Integrase Inhibitors Dolutegravir Blocks integration of viral cDNA 
by inhibiting integrase.  
Raltegravir Blocks integration of viral cDNA 
through interfering with viral 
integrase. Mutations at 
Y143H/R/C, Q148H/R/K, and 
N155H renders Raltegravir 
infective(Hare et al. 2010).  
Protease Inhibitors (PIs) Atazanavir First protease inhibitor. A 
structural analog of protease 
transition state(Bold et al. 1998).  
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Darunavir A modification of Amprenavir, 
with bis-tetrahydrofuran replacing 
tetrahydrofuran(Lefebvre and 
Schiffer 2009). 
Fosamprenavir Similar to amprenavir, however, it 
is a precursor with the host 
metabolizing it into amprenavir, 
prolonging the drug’s half-
life(Eron et al. 2006).  
Saquinavir A transition structural analog 
when protease cleaves 
phenylalanine and proline(Reich 
et al. 1995).  
Tipranavir The only nonpeptidomimetic HIV 
protease inhibitors. It interacts 
with Ile50 of the protease(Y. 
Wang, Lv, and Chu 2015).  
Amprenavir Amprenavir fits inside the active 
site with benzyle group at P1 site, 
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and isobutyl group at P1’ site(Y. 
Wang, Lv, and Chu 2015). 
Table 1: HIV-1 drug class and mechanism of action 
Although a functional cure cannot be achieved with triple and/or quadruple drug 
regimens, life expectancy has been increased with HAART treatment. Present day 
emphasis has thus changed to improving the quality of life of those chronically infected 
with HIV. Studies have shown that even with HAART, there is low level of inflammation 
due to establishment of chronic HIV infection(Deeks, Tracy, and Douek 2013). This 
inflammatory response in the systemic circulation has been linked as key driver of HIV-
associated morbidities in both periphery and CNS, such as HIV- associated 
neurocognitive disorders (HAND) (Canet et al. 2018).  
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Figure 4: Aging and Severity of HIV infection correlates with Neuro 
Cognitive Impairment.(Nasi et al. 2014) Graph shows that the length in time of 
HIV infection, and the severity of HIV infection, corresponding to the 
development of HIV associated neurocognitive disorders. Chronic low-level 
inflammation caused by persistent systemic immune activation by HIV-1 
infection, even under successful HAART treatment, causes development of 
HAND (HIV associated neurocognitive disorders) in the CNS through activated 
monocyte migration to the central nervous system.  
Despite HAART treatment, one form of long-term HIV-1 cDNA exists in 
episomal form. After reverse transcription of viral RNA into double stranded linear 
cDNA, cDNA forms into a pre-integration complex(PIC) and shuttled to the nucleus for 
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chromosome integration(Suspène and Meyerhans 2012a). Host integration of viral cDNA 
requires viral integrase, which can be inhibited by integrase inhibitors such as 
Raltegravir(Ral), and Elvitegravir(EVG)(Quashie, Mesplède, and Wainberg 2012). When 
integrase activity is inhibited, unintegrated viral DNAs form into 1-LTR, and 2-LTR 
circles through homologous recombination, and Non-Homologous End Joining, 
respectively(Kilzer et al. 2003). In-vitro, infecting cells with HIV in the presence of 
integration inhibitor such as Raltegravir, or using integrase-defective mutant viruses such 
as D116N(Vermeire et al. 2016), 2-LTR circles have been shown to be formed. 
Naturally, more than 90% of HIV-1 transcripts fail to integrate in vivo, and the 
unintegrated linear DNA either becomes either degraded, or formed into 1-LTR or 2-LTR 
circles(Suspène and Meyerhans 2012b).   
Several studies have shown that these unintegrated DNA have a long half-life and 
persist at least 30 days in macrophages, without significant degradation starting from the 
7th day of infection(Brussel and Sonigo 2004). Studies have shown that presence of HIV-
1 Vpr is required for transcription from these unintegrated 2LTR circles(Gillim-Ross, 
Cara, and Klotman 2005). 
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2 LTR Circles 
Figure 5: Long Terminal Repeats (LTRs) is one of the products of Linear cDNA 
(Hamid, Kim, and Shin 2017) HIV goes through reverse transcription, and becomes viral 
cDNA. The viral cDNA have three fates: it will integrate into the host chromosome, 
become degraded, or circularized to become LTRs.  
As life expectancy increases with HAART treatment, people focus on the quality 
of life of those infected with HIV. Low level of inflammation has been observed in 
chronically infected HIV+ patients on HAART (Deeks, Tracy, and Douek 2013). This 
inflammatory response in the systemic circulation has been linked as key driver of HIV 
pathogenesis in both periphery and CNS, causing HIV- associated neurocognitive 
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disorder(Eggers et al. 2017). Interestingly, episomal forms of viral DNA, including 2-
LTR circles can express not only early viral genes such as Tat, Nef and Rev, but also late, 
unspliced or partially viral transcripts(Sloan and Wainberg 2011). Furthermore, several 
studies have shown that these unintegrated DNA have a long half-life and persist at least 
30 days in macrophages(Gillim-Ross, Cara, and Klotman 2005).  
Vpr 
 HIV is composed of 3 structural proteins (Gag, Pol and Env), 2 regulatory 
proteins (Tat and Rev), and 4 accessory proteins. These 4 accessory proteins: Nef, Vif, 
Vpu and Vpr, are known to help pathogenesis by degradation of host proteins (viral 
restriction factors) at different stages of viral life cycle. Vpr is one of the accessory 
proteins, and has 96 amino acid, and 14kDa in size(Kogan and Rappaport 2011). It is 
incorporated in HIV-1 virion by interaction at p6 region of HIV Gag(Selig and Erdtmann 
1999). It has at least two nuclear import signals, and one nuclear export signal(Jenkins et 
al. 1998).  
 
 18 
 
Figure 6: Vpr NMR structure showing 96AA and 3 alpha-helices(Morellet et 
al. 2003) The highly conserved helix 1 and helix 3 is associated with virion 
incorporation and DCAF1 interaction, respectively. 
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Figure 7: Functions of Vpr(Guenzel and Benichou 2014) Numerous functions of 
Vpr is highlighted in red. Some notable functions include G2 cell cycle arrest, cell 
death, regulation of gene expression, and triggering DNA damaging response, 
degradation of host proteins through DCAF1-DDB1-Cul4 ubiquitin ligase 
complex 
Despite many years of research, Vpr remains a very mysterious protein, with 
many attributed functions, including transcriptional activation, induction of cell death via 
apoptosis, impairment of mitochondrial functions, degradation of various DNA Damage 
response proteins, and most importantly, induction of G2/M cell cycle arrest(Guenzel and 
Benichou 2014). G2/M cell cycle arrest is the result of Vpr binding to CUL4A(Cullin 
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4A)-RBX1(E3 ubiquitin ligase)-DDB1(DNA damage binding protein 1)-DCAF1(DDB1-
Cullin4A-associated Factor)/VprBP E3 ubiquitin ligase complex targeting numerous 
DDR (DNA damage response) proteins for degradation(Wu et al. 2016, 1). Interestingly, 
previous studies have suggested HIV-1 LTR is most transcriptionally active in the G2/M 
phase of the cell cycle arrest(Goh et al. 1998) and that Vpr-mediated G2/M arrest results 
in enhanced LTR mediated viral gene expression(Goh et al. 1998; Gummuluru and 
Emerman 1999). 
 
 
Figure 8: Vpx and Vpr hijack the same ubiquitin-proteasome pathway to 
degrade different host proteins.(Chougui and Margottin-Goguet 2019) Vpr and 
Vpx acts as different adapters for different host proteins, and degrades them 
through the hos Cullin-RING ligase ubiquitination pathway. Vpx, a paralog of 
Vpr, targets SAMHD1, while Vpr does not.   
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Vpx from HIV-2 and SIVsmm (sooty mangabey monkeys) has many similarities, 
but also differences to HIV-1 Vpr. They are thought to originate from a common 
precursor, and a gene duplication event resulted in divergence(Bergamaschi et al. 2009). 
Both Vpx, and Vpr use DCAF to target host genome for degradation by binding to it 
through the third alpha-helix. However, Vpx is known to target SAMHD1 for 
degradation, while HIV-1 Vpr does not(Chougui et al. 2018). SAMHD1 is a cellular 
restriction factor that hydrolyzes dNTPs, and keeps intracellular dNTPs at a low level, 
thus inhibiting reverse transcription of viral RNA in the cytoplasm(Bakir 2018). In 2018, 
Morel et al, and Yurkovetskiy et al. separately published in Nature Microbiology, that 
another target of Vpx-DCAF1 complex is TASOR, a component within the HUSH 
complex. 
HUSH Complex 
 
Figure 9: NP220 mediates silencing of unintegrated retroviral DNA.(Zhu et 
al. 2018) NP220, a DNA binding protein, first attaches to cytidine-rich sequence 
rich, and then recruits the HUSH complex, and a HDAC. The HUSH complex 
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then recruits SETDB1, a methyl transferase, and HDAC, a histone deacetylase, to 
silence gene expression. Cytidine rich sequences are often found in viral LTR 
(Long Terminal Repeat) regions that regulate viral gene expression.   
 
HUSH complex is composed of TASOR MPP8, PPHLN1(Tchasovnikarova et al. 
2015). One of the identified downstream event is recruitment of SETDB1, an H3K9me3 
(Histone 3 lysine9 trimethylation) methyltransferase responsible for silencing of 
endogenous genes, and retroviral genes(Yurkovetskiy et al. 2018). Vpx is shown to target 
TASOR for degradation, and knockdown of TASOR in CD4+ T cells had same effect as 
adding Vpx for increasing reporter gene expression(Chougui et al. 2018, 2). MPP8 is the 
first protein of the HUSH complex to be recruited, and subsequently, TASOR is 
recruited. MPP8 depletion resulted in loss of methylation at H3K9. Since, DNA 
methylation suppresses transcription, and histone acetylation activates transcription 
through chromatin compaction, and relaxation, previous studies have hypothesized that 
transcriptional repression of viral LTR is mediated by HUSH complex’s recruitment of 
SETDB1 and methylating LTR for repression(Cuellar et al. 2017).  
Another recent study showed that NP220 binds unintegrated retroviral DNA (LTR 
regions that are rich in cytidine). NP220 binds to double-stranded DNA that has high 
numbers of cytidines(Zhu et al. 2018). It has a DNA binding domain, and a C terminal 
zinc finger motif, both of which are required for silencing of unintegrated murine 
leukemia virus (MLV), a simple retrovirus(G. Z. Wang, Wang, and Goff 2016). NP220 is 
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then recruits the HUSH complex. This complex then recruits SETDB1 to deposit methyl 
modifications on histone proteins bound to viral DNA. NP220 also recruits two other 
enzymes called HDAC1 and HDAC4(Romani et al. 2016a). They are from a family of 
enzymes called histone deacetylases, which catalyze the removal of acetyl groups from 
histones. A decrease in the level of histone acetylation can repress gene expression. 
 Interestingly, both Vpx addition, and TASOR knockdown resulted in increase in 
endogenous LINE-1 expression in embryonal carcinoma cells, suggesting that the HUSH 
complex not only suppresses exogenous viral transcription, but also plays a role in 
endogenous viral transcriptional suppression. Upon loss of HUSH mediated repression of 
viral transcription, enhanced viral gene expression can lead to pathogenic consequences. 
For instance, both viral RNAs and protein can be sensed by the host, and stimulate IFN 
production, resulting in induction of inflammatory responses. In areas of the body where 
anti-viral drugs are difficult to penetrate, such as lymph nodes and the CNS, chronic 
inflammation may persist due to low-level viral transcription from these episomal, and 
long-lasting 2-LTR circles. 
 
Hypothesis and Specific Aim 
My aim was to determine the mechanism by which Vpr can promote viral gene 
expression from unintegrated viral DNA. I hypothesized that Vpr enhances viral gene 
expression from unintegrated viral DNA through degradation of HUSH complex 
subunits. To test this hypothesis, I created HeLa cell lines in which expression of HUSH 
components, including the upstream SETDB1 protein, was diminished by use of targeted 
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shRNAs. Stable cell lines with reduced expression of TASOR, MPP8, PPHLN or 
SETDB1 were assessed for unintegrated viral DNA expression upon infection with Vpr 
null (ΔVpr) or Wildtype(WT) HIV. Surprisingly, I found that decreased HUSH complex 
expression failed to rescue viral gene expression from unintegrated viral DNA in cells 
infected with HIV/ΔVpr. These results suggest existence of an alternative host 
mechanism of transcriptional silencing of HIV-1 LTR that is counteracted by Vpr, whose 
identity remains to be discovered. 
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METHODS 
shRNA Plasmid: 
shRNA-encoding plasmids were constructed by replacing pLKO.1 stuffer 
sequence with the designed DNA oligos containing shRNA sequences using enzymes 
AgeI and EcoRI. The shRNA target sequences for each respective knockdown are:  
SETDB1: ACCCGAGGCTTTGCTCTTA 
TASOR: GAGGAAGCTTGAGGATCTA 
MPP8: AAGAAGACCCCGAGAAAGG 
PPHLN1: AGCTAACCACTCGCTCTAA 
VLP and Virus production:  
 shRNA-expressing lentivectors were produced from HEK 293T cells via calcium-
phosphate-mediated transfection method(“Calcium Phosphate–Mediated Transfection of 
Eukaryotic Cells” 2005). Briefly, HEK 293T cells were maintained in 
DMEM(Invitrogen) containing 10% heat-inactivated FBS(Invitrogen), and 1% Pen-Strep. 
10 ml of HEK293T cells are seeded on 10cm dishes at 2.5*105 cells/ml the day before 
transfection. shRNA vector, expression vector pCMV-VSV-G(Addgene plasmid # 8454), 
and packaging construct psPAX2(Addgene plasmid # 12260) were added at 5:5:1 ratio. 
WT and Vpr Null viruses were transfected using plasmids Bru∆env-luc/G or  
Bru∆envVprFS-luc/G, respectively, together with pCMV-VSV-G. MLV viruses were 
generated by transfection using plasmids pCL10A1, pCMV-VSV-G, and LlucSN. All 
vectors express luciferase(Nazari et al. 2017).  
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 Cells were washed 14 hours post-transfection, and cell medium harvested 24 hrs 
after wash. Culture medium was then filtered through 0.45 um pore filters, and 
concentrated via ultracentrifugation(SW32Ti, Beckman Coulter), using 20% sucrose 
cushion. The condition for ultracentrifugation is 24,000 rpm, 1.5 hours, 4°C. 
Concentration of HIV VLPs was quantified using p24Gag ELISA (Akiyama et al. 2018). 
  
Knockdown Cell lines: 
HeLa cells were cultured in DMEM containing 10% heat-inactivated FBS, and 
1% Pen-Strep. Prior to infection, 10 mL of cells at 2.5*105 cells/ml were seeded in 10cm 
dishes. 24 hours post seeding, cells are at ~50% confluency. HeLa cells were infected 
with shRNA VLPs in the presence of 10ug/ml polybrene. 24hrs post infection, shRNA-
transduced cells were selected with 10ug/ml Puromycin(InvivoGen) for 10 days. 
Knockdown efficiency was confirmed using RT-qPCR. 
 Total mRNA was isolated from 3*106 cells (RNeasy kit, QIAGEN), and reverse 
transcribed to cDNA using RT-qPCR kit (Superscript III, Invitrogen). cDNA was then 
quantitated using SYBR green(Thermo Scientific) with GAPDH normalization. All the 
primers used for quantitative PCR are: 
 
GAPDH_forward: CAAGATCATCAGCAATGCCT 
GAPDH_reverse: AGGGATGATGTTCTGGAGAG 
SETDB1_forward: CGAATTCTGGGCAAGAAGAG 
SETDB1_reverse: TCAGCAGGAGGGTGGTAATC 
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TASOR_forward: AAAAGGATTACATGTGGGTC 
TASOR_reverse: GCATACCTAGAAAGATAGACAC 
MPP8_forward: GATGAAGGCCTGTAAAAGAG 
MPP8_reverse: CACATTGTTAGACTGCTTCG 
 PPHLN1_forward: AAACACAACACATGGGATAG 
 PPHLN1_reverse: AACCTGTTCAATCTCTTTGG 
Analysis of knockdown used 2 -∆∆Ct method   
 
Infection of Knockdown Cells: 
Knockdown cells were seeded at 104 cells/well in 96 well flat-bottom plates. 24 
hrs post seeding, virus containing 10 ng p24Gag was used to infect cells in each well. For 
cells that were pretreated with Raltegravir, 30 uM final concentration was used to 
incubate the cells 30 minutes prior to infection. A virus master-mix was used to minimize 
well-to-well discrepancy, along with 10ug/ml polybrene (Millipore). Cells were 
spinnoculated for 1hr at RT and 2300 rpm. 
 
Luciferase activity assay: 
3 days post infection, cells were lysed using Glo-lysis buffer (Promega), and 
luciferase activity was analyzed using luciferase assay system (Bright-Glo, Promega). 
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RESULTS and CONCLUSION 
HeLa cells were transduced with lentivectors expressing shRNAs against HUSH 
complex subunits. Note that shRNA knockdown for any of the targets did not achieve 
100% knockdown efficiency. PPHLN1 achieved the best knockdown with 99% 
efficiency. This almost complete knockdown was crucial in the latter experiments 
showing that HUSH is involved in suppressing MLV viral DNA expression. 
After confirming knockdown efficiency of HUSH complex proteins and SETDB1 
(Figure 10), cells were infected with WT or Vpr-null viruses in the presence or absence 
of raltegravir. D116N viruses, which are integrase null viruses, are used concurrently to 
re-affirm Raltegravir results. After 3 days post infection, cells were lysed , and cell 
lysates were processed for luciferase activity (Figure 11). 
Figure 10: Knockdown of HUSH complex subunits and SETDB1 in HeLA cells.  
The expression of HUSH complex subunits and SETDB1 in HeLa cells 
transduced with lentivectors expressing shRNAs against SETDB1, TASOR, MPP8, 
PPHLN1 or scrambled sequence was determined by RT-qPCR. The data reported is the 
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percent decrease of the relative expression of RNA compared to that in scrambled 
shRNA-transduced cells. Data shown as average of 2 experiments.  
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Figure 11a
                                                                                   
Figure 11b 
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Figure 11c 
Figure 11: Knockdown of HUSH expression fails to rescue  unintegrated expression 
in Vpr-null virus infected cells. Hela cells stably expressing shRNAs were infected with 
luciferase expressing WT or Vpr-null viruses (10ng p24gag) in the absence (A) or 
presence (B) of raltegravir. Alternatively, cells were infected with viruses expressing 
catalytically inactive integrase mutant (C). Cells are lysed 3 days post infection, and 
analyzed for luciferase activity. The data is reported as relative light units per equal 
amounts of cell lysates and is the mean of 3 independent infections. 
 
When cells are not treated with Raltegravir (Figure 11a), all cells showed higher 
luciferase expression in ΔVpr infected cells. In contrast, luciferase expression from 
unintegrated viral DNA (in presence of Raltegravir) was greatly enhanced in WT (Vpr 
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containing) virus infected cells compared to Vpr-null virus infections (Figure 11b). 
D116N mutant virus have mutated integrase that is deficient in integration (Figure 11c). 
It is the same as addition of Raltegravir to block integration. These results suggest that 
Vpr is needed for unintegrated viral DNA expression. Surprisingly, knockdown of 
individual HUSH complex subunit expression, failed to rescue unintegrated viral gene 
expression in Vpr-null virus infected cells. Thus, HUSH complex is concluded to not 
play a role in the suppression of unintegrated viral expression.  
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Figure 12: Infection of HUSH component knockdown cells with MLV 
expressing virus. Cells are lysed 3 days post infection, and analyzed through 
luciferase readout. Without PPHLN1, one of the three HUSH complex proteins, 
unintegrated MLV viral DNA is expressed. 
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As previously discussed, HUSH complex is known to play a role in suppressing 
transcription from unintegrated MLV viral DNA(Zhu et al. 2018). In agreement with 
these previously published findings, when HUSH complex is knocked down, specifically 
the PPHLN1 protein, we observed a significant increase in luciferase expression 
compared to infections of scramble shRNA-expressing cells in the presence of 
raltegravir. This confirms that HUSH complex plays a role in suppressing unintegrated 
MLV viral DNA. There is no increase in luciferase expression from other HUSH 
complex knockdowns, namely TASOR and MPP8, possibly because these two cell lines 
did not achieve greater than 90% knockdown of the HUSH proteins (Figure 10). 
  
Future Study 
 The long-lasting viral reservoirs harboring 2-LTR circles have been thought to 
contribute viral persistence, viral relapse, and chronic inflammation, which causes HIV- 
associated neurocognitive disorders (HAND) and other morbidities. The amount of 2-
LTR viral DNA elevates when integration is blocked using antiretroviral drugs such as 
raltegravir, an integrase inhibitor. Furthermore, silencing viral gene expression from 
episomal forms of viral DNA such as 2LTR circles is hypothesized to be linked to HUSH 
complex.  
Previous papers have shown that MLV, another class of retrovirus, have their 
viral DNA wrapped with histones upon nuclear entry at nuc-0 and nuc-1 positions, which 
overlaps LTR region of viral DNA that regulates transcription(Romani et al. 2016b). 
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Histone modifying complexes such as HUSH complex, can then modify these histones to 
activate or suppress transcription from 2-LTR circles. Vpr is hypothesized to play a role 
in influencing the modification of histones to activate transcription from 2-LTR circles.  
However, in our experiments, the opposite effect is seen in infections with HIV-1. 
Knockdown of HUSH complex resulted in decreased expression from proviruses in both 
WT and Integrase Null viruses. One hypothesis is that HUSH complex plays a role in 
cellular fitness, so knocked-down cell lines are less healthy overall. One method to 
circumvent this is to use a SETDB1 inhibitor, 382190-5MG, to treat HeLa cells before 
infection, instead of creating HUSH knockdown. Importantly, we show that Vpr is 
required for enhancing expression from unintegrated viruses, and that HUSH complex 
does not play a role in suppressing expression from unintegrated HIV-1 DNA. This result 
is contrary to our hypothesis, and further investigation is needed to find the reason.  
Future knockout studies might include using pooled CRISPR library to 
knockdown 19,050 individual genes in HeLa cells, and determine whether enhanced viral 
expression from unintegrated viral DNA is also observed in cells infected with Vpr-
deficient virus. This should reveal the target which Vpr degrades to facilitate 
transcription of unintegrated viral DNA.  
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